Krystal Biotech Ownership
| KRYS Stock | USD 156.07 0.23 0.15% |
Shares in Circulation | First Issued 2016-09-30 | Previous Quarter 29.6 M | Current Value 29.9 M | Avarage Shares Outstanding 18.5 M | Quarterly Volatility 8.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Krystal |
Krystal Stock Ownership Analysis
About 12.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To find out more about Krystal Biotech contact the company at 412 586 5830 or learn more at https://www.krystalbio.com.Besides selling stocks to institutional investors, Krystal Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Krystal Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Krystal Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Krystal Biotech Quarterly Liabilities And Stockholders Equity |
|
Krystal Biotech Insider Trades History
About 12.0% of Krystal Biotech are currently held by insiders. Unlike Krystal Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Krystal Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Krystal Biotech's insider trades
Krystal Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Krystal Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Krystal Biotech backward and forwards among themselves. Krystal Biotech's institutional investor refers to the entity that pools money to purchase Krystal Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jennison Associates Llc | 2024-09-30 | 410.1 K | Amvescap Plc. | 2024-09-30 | 365.6 K | Nuveen Asset Management, Llc | 2024-09-30 | 311.9 K | Goldman Sachs Group Inc | 2024-09-30 | 301.4 K | Lord, Abbett & Co Llc | 2024-09-30 | 284.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 275.8 K | Franklin Resources Inc | 2024-09-30 | 243.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 240.2 K | Northern Trust Corp | 2024-09-30 | 238.7 K | Fmr Inc | 2024-09-30 | 4.3 M | Blackrock Inc | 2024-09-30 | 4 M |
Krystal Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Krystal Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Krystal Biotech Outstanding Bonds
Krystal Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Krystal Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Krystal bonds can be classified according to their maturity, which is the date when Krystal Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Krystal Biotech Corporate Filings
8K | 18th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.